Advertisement

Unmasking of a hepatitis c genotype 3a/1b dual infection in an individual treated with elbasvir/ grazoprevir

  • Rob W. van der Pluijm
    Correspondence
    Corresponding author. , Amsterdam University Medical Centers, University of Amsterdam, D3-209, Department of Internal Medicine, Division of Infectious Diseases, Meibergdreef 9, 1105AZ Amsterdam, The Netherlands.
    Affiliations
    Division of Infectious Diseases, Amsterdam Infection and Immunity Institute, Amsterdam University Medical Centers, location University of Amsterdam, The Netherlands
    Search for articles by this author
  • Loek P. Smits
    Affiliations
    Division of Infectious Diseases, Amsterdam Infection and Immunity Institute, Amsterdam University Medical Centers, location University of Amsterdam, The Netherlands
    Search for articles by this author
  • Sjoerd P. Rebers
    Affiliations
    Department of Medical Microbiology and Infection Prevention, Amsterdam University Medical Centers, location University of Amsterdam, The Netherlands
    Search for articles by this author
  • Janke Schinkel
    Affiliations
    Department of Medical Microbiology and Infection Prevention, Amsterdam University Medical Centers, location University of Amsterdam, The Netherlands
    Search for articles by this author
  • Marc van der Valk
    Affiliations
    Division of Infectious Diseases, Amsterdam Infection and Immunity Institute, Amsterdam University Medical Centers, location University of Amsterdam, The Netherlands
    Search for articles by this author
Published:November 22, 2022DOI:https://doi.org/10.1016/j.jhep.2022.11.016
      Pan-genotypic direct-acting antivirals (DAA) for the treatment of hepatitis C viral (HCV) infections remain expensive. To reduce costs, genotype-specific regimes could be considered, according to the EASL guidelines.
      • Pawlotsky J.M.
      • Negro F.
      • Aghemo A.
      • Berenguer M.
      • Dalgard O.
      • Dusheiko G.
      • et al.
      EASL recommendations on treatment of hepatitis C: Final update of the series☆.
      The presence of mixed genotype HCV infections has been reported, and detection rates have been found to be method dependent.
      • Fernández-Caso B.
      • Fernández-Caballero J.Á.
      • Chueca N.
      • Rojo E.
      • de Salazar A.
      • García Buey L.
      • et al.
      Infection with multiple hepatitis C virus genotypes detected using commercial tests should be confirmed using next generation sequencing.
      The identification of a second infection with a different genotype could be of importance when considering genotype specific DAA.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Hepatology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Pawlotsky J.M.
        • Negro F.
        • Aghemo A.
        • Berenguer M.
        • Dalgard O.
        • Dusheiko G.
        • et al.
        EASL recommendations on treatment of hepatitis C: Final update of the series☆.
        J Hepatol. 2020;
        • Fernández-Caso B.
        • Fernández-Caballero J.Á.
        • Chueca N.
        • Rojo E.
        • de Salazar A.
        • García Buey L.
        • et al.
        Infection with multiple hepatitis C virus genotypes detected using commercial tests should be confirmed using next generation sequencing.
        Sci Rep. 2019;
        • Murphy D.G.
        • Willems B.
        • Deschênes M.
        • Hilzenrat N.
        • Mousseau R.
        • Sabbah S.
        Use of sequence analysis of the NS5B region for routine genotyping of hepatitis C virus with reference to C/E1 and 5′ untranslated region sequences.
        J Clin Microbiol. 2007;
        • Ng T.I.
        • Tripathi R.
        • Reisch T.
        • Lu L.
        • Middleton T.
        • Hopkins T.A.
        • et al.
        In vitro antiviral activity and resistance profile of the next-generation hepatitis C virus NS3/4A protease inhibitor glecaprevir.
        Antimicrob Agents Chemother. 2018;